[go: up one dir, main page]

MA40325A - Methods and compositions for diagnosing, prognosing, and confirming preeclampsia - Google Patents

Methods and compositions for diagnosing, prognosing, and confirming preeclampsia

Info

Publication number
MA40325A
MA40325A MA040325A MA40325A MA40325A MA 40325 A MA40325 A MA 40325A MA 040325 A MA040325 A MA 040325A MA 40325 A MA40325 A MA 40325A MA 40325 A MA40325 A MA 40325A
Authority
MA
Morocco
Prior art keywords
methods
prognosing
preeclampsia
diagnosing
confirming
Prior art date
Application number
MA040325A
Other languages
French (fr)
Inventor
Matthew Cooper
Lyndal Hesterberg
Evangelos Hytopoulos
Eric Kunkel
Kimberly Schwartz
Original Assignee
Matthew Cooper
Lyndal Hesterberg
Evangelos Hytopoulos
Eric Kunkel
Kimberly Schwartz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthew Cooper, Lyndal Hesterberg, Evangelos Hytopoulos, Eric Kunkel, Kimberly Schwartz filed Critical Matthew Cooper
Publication of MA40325A publication Critical patent/MA40325A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Methods, compositions, kits, algorithms, systems, specialized computer, software, business methods and reagents are provided for diagnosing, prognosing, monitoring, characterizing, determining the severity of preeclampsia, confirming the presence of pree
MA040325A 2014-07-30 2015-07-30 Methods and compositions for diagnosing, prognosing, and confirming preeclampsia MA40325A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462031132P 2014-07-30 2014-07-30
US201462031834P 2014-07-31 2014-07-31
US201562115077P 2015-02-11 2015-02-11

Publications (1)

Publication Number Publication Date
MA40325A true MA40325A (en) 2016-02-04

Family

ID=55218328

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040325A MA40325A (en) 2014-07-30 2015-07-30 Methods and compositions for diagnosing, prognosing, and confirming preeclampsia

Country Status (5)

Country Link
EP (1) EP3175239A1 (en)
CN (1) CN107155350A (en)
CA (1) CA2956646A1 (en)
MA (1) MA40325A (en)
WO (1) WO2016019176A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017148854A1 (en) * 2016-02-29 2017-09-08 Roche Diagnostics Gmbh Igfbp-7 as a marker in preeclampsia
FR3057070B1 (en) * 2016-10-04 2018-11-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) DIAGNOSTIC AND PRONOSTIC EARLY PREECLAMPSY
CN107312846A (en) * 2017-07-12 2017-11-03 北京赛尔维康生物医学科技有限公司 Application of the CAPG and PTGIS genes in scoliosis detection kit is prepared
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
EP3701043B1 (en) * 2017-10-23 2023-11-22 CZ Biohub SF, LLC A noninvasive molecular clock for fetal development predicts gestational age and preterm delivery
AU2019218548A1 (en) * 2018-02-09 2020-09-03 Metabolomic Diagnostics Limited Methods of predicting pre term birth from preeclampsia using metabolic and protein biomarkers
CN108717123A (en) * 2018-04-25 2018-10-30 卢英 A kind of method of joint-detection sFlt-1/PLGF and HLA-G detections pre-eclampsia
JP7557463B2 (en) * 2018-07-20 2024-09-27 エフ． ホフマン－ラ ロシュ アーゲー Prediction of preeclampsia based on IGFBP-7
KR20200049365A (en) * 2018-10-31 2020-05-08 서울대학교산학협력단 Biomarkers in predicting gestational diabetes mellitus and pregnancy associated hypertension
CN109554479A (en) * 2019-01-21 2019-04-02 中南大学 Application of the PIGC gene in preparation diagnosis for liver cancer and Index for diagnosis preparation
CN109919054B (en) * 2019-02-25 2023-04-07 电子科技大学 Machine vision-based reagent card automatic classification detection method
CN110596386B (en) * 2019-09-20 2020-06-02 四川大学华西医院 Application of EGFLAM autoantibody detection reagent in preparation of lung cancer screening kit
CN112710836A (en) * 2019-10-25 2021-04-27 成都敬守务成医疗科技有限责任公司 Application of human leukocyte antigen G marker and kit
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS
CN112180098B (en) * 2019-12-06 2023-02-17 中山大学 Screening method of placenta-related disease marker and marker
CN111257445B (en) * 2020-01-22 2022-09-09 上海交通大学医学院附属仁济医院 Product and method for SLE pregnant woman disease monitoring and fetus outcome prediction
CN113495147A (en) * 2020-03-19 2021-10-12 首都医科大学附属北京世纪坛医院 Application of urine alpha 2-macroglobulin and polypeptide fragment thereof in gestational diabetes
CN112305220B (en) * 2020-06-03 2021-07-23 四川大学华西第二医院 Application and products of cathepsin Z in early warning and diagnosis of preeclampsia
KR102233909B1 (en) * 2020-07-13 2021-03-30 서울대학교산학협력단 Biomarkers in predicting gestational diabetes mellitus and pregnancy associated hypertension
CN111951969A (en) * 2020-08-05 2020-11-17 中翰盛泰生物技术股份有限公司 Application of HBP in high-risk pregnancy prediction
GB202012830D0 (en) * 2020-08-17 2020-09-30 Univ Tartu Method of prognosing preeclampsia
CN112175963A (en) * 2020-09-30 2021-01-05 安徽省天长市周氏羊业有限公司 SPP1 gene and method for evaluating developmental quality of golgi in single follicle of sheep
CN112535886B (en) * 2020-11-12 2022-07-12 杭州苏铂科技有限公司 Method for removing CTAB in gold nanorod solution
CN112946299B (en) * 2021-01-29 2022-11-29 暨南大学 Application of product of quantitative FTL in preparation of preeclampsia diagnosis tool
CN112946283B (en) * 2021-01-29 2022-11-29 暨南大学 Application of quantitative A2M products in the preparation of diagnostic tools for preeclampsia
CN113092777B (en) * 2021-03-26 2023-11-14 泰达国际心血管病医院 Method for screening severe preeclampsia patients in early gestation period
CN118451327A (en) * 2021-11-11 2024-08-06 Nx产前公司 Methods of preparing and analyzing samples for biomarkers associated with placental implantation
CN117867094A (en) * 2022-10-10 2024-04-12 天津云检医疗器械有限公司 Biomarkers, kits, and methods for preeclampsia risk prediction, assessment, or diagnosis
CN117647653B (en) * 2023-12-22 2024-05-07 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Biomarker related to preeclampsia and application thereof
CN118593717A (en) * 2024-05-31 2024-09-06 厦门特宝生物工程股份有限公司 A pharmaceutical composition for treating and/or preventing preeclampsia and its application
CN119230113A (en) * 2024-09-30 2024-12-31 常州市妇幼保健院 Classifier and training system for early identification and severity prediction of placenta accreta disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1839056B1 (en) * 2004-12-21 2011-08-03 Yale University Diagnosis of preeclampsia
US20100016173A1 (en) * 2008-01-30 2010-01-21 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
US20150099655A1 (en) * 2012-05-08 2015-04-09 The Board Of Trustees Of The Leland Stanford Junior University Methods and Compositions for Providing a Preeclampsia Assessment
EP2890816B1 (en) * 2012-08-30 2019-06-05 Ansh Labs LLC Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia

Also Published As

Publication number Publication date
EP3175239A1 (en) 2017-06-07
CN107155350A (en) 2017-09-12
WO2016019176A1 (en) 2016-02-04
CA2956646A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
MA40325A (en) Methods and compositions for diagnosing, prognosing, and confirming preeclampsia
EP3227830B8 (en) Methods, systems, and apparatuses for quantitative analysis of heterogeneous biomarker distribution
EP3194624A4 (en) Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor
MX2020010147A (en) Methods for predicting risk of interstitial pneumonia.
GB2539852A8 (en) System and method for managing supply of service
MX2015010174A (en) Diagnostic tools to predict onset of preeclampsia.
EP3176268A4 (en) Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof
EP3220315A4 (en) System, method, and program for predicting information
EP3121584A4 (en) Method for predicting remaining service life of hose and method for diagnosing deterioration of hose
EP3511422A3 (en) Methods and compositions for diagnosing, prognosing, and treating endometriosis
EP3798316A3 (en) Genes and gene signatures for diagnosis and treatment of melanoma
EP3148426A4 (en) Method, system and software for assessing extubation failure
EP3693742A3 (en) Methods of detecting prostate cancer
MX2018004005A (en) Cell potency assay.
MY200184A (en) Biomarker
EP3111223C0 (en) LUNG CANCER BIOMARKERS, RELATED METHODS AND KITS
MX2016015759A (en) Dna methylation status as a biomarker of alcohol use and abstinence.
WO2014160237A3 (en) Methods of prognosing preeclampsia
MY182547A (en) Polymerase chain reaction detection system
EP4250299A3 (en) Genes and gene signatures for diagnosis and treatment of melanoma
EP3172572A4 (en) Biomarkers for assessment of preeclampsia
EP3174322A4 (en) Method for deleting notification resource, and common service entity
AU2017269968A1 (en) Methods and systems using C4 gene copy number and cell-bound complement activation products for identification of lupus and pre-lupus
WO2013173500A3 (en) Method for predicting recurrence of melanoma using mirna alterations
UA95580U (en) METHOD OF FORECASTING FRAGMENT FRAGMENT